GlassScriptPhysician profile
Roxanne Rezaei
NPI 1316569049
$1,502.27
in general payments reported to CMS, 2019-2025
25 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $605 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $239.80 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Daiichi Sankyo INC. | $159.81 | 2023-2025 | Injectafer |
| Lilly USA, LLC | $139.38 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $104.77 | 2023-2025 | |
| Novo Nordisk INC | $97.59 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $89.06 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.39 | 2024-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $62.67 | 2023-2025 | Dexcom G6 Transmitter |
| Lexicon Pharmaceuticals, INC. | $54.98 | 2024 | |
| Radius Health, INC. | $53.36 | 2025 | Tymlos |
| Pfizer INC. | $53.24 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $49.80 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $38.16 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $35.50 | 2025 | |
| Exact Sciences Corporation | $32.25 | 2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.71 | 2025 | |
| Edwards Lifesciences Corporation | $30.13 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $30.06 | 2024-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.79 | 2024 | Ofev |
| Dynavax Technologies Corporation | $20.52 | 2023-2025 | Heplisav-B |
| Echosens North America, INC. | $18.67 | 2025 | Fibroscan |
| Corcept Therapeutics | $17.65 | 2025 | Korlym |
| Amgen INC. | $17.27 | 2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $16.25 | 2024 | Trelegy Ellipta |
| Scpharmaceuticals INC. | $15.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Rezaei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.